Friday, December 23, 2022

Cellectis Announces First Dosing of a Patient with its - GlobeNewswire

... an end-to-end cell and gene therapy company, from discovery & product development, transfer, and cGMP manufacturing to clinical development.
https://www.google.com/url?rct=j&sa=t&url=https://www.globenewswire.com/news-release/2022/12/22/2578926/0/en/Cellectis-Announces-First-Dosing-of-a-Patient-with-its-In-house-Manufactured-Product-Candidate-UCART22-for-the-treatment-of-r-r-B-cell-ALL.html&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AOvVaw1CYmG58hVRUoI4vd7sK1uA
-

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)

2 muggers captured by RU students on campus - UNB

Rayhanul Ferdous, a student of Genetic Engineering and Biotechnology department who had his phone stolen told UNB: “I was walking on the eas...